Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: 48-Week Results From FOREST-HCM

A Plain Language Summary of the SEQUOIA-HCM Study: Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy

The Effect of Omecamtiv Mecarbil on Outcomes Analysed Using the Win Ratio: an Exploratory Analysis of GALACTIC-HF

Effect of Aficamten Treatment on Patients with Hypertrophic Obstructive Cardiomyopathy by Geographical Region

Associations Between Age and Sex and Cardiovascular Outcomes in Patients With Non-Obstructive Hypertrophic Cardiomyopathy

Efficacy and Safety of Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy and Mild Symptoms

Efficacy of Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy and Mild Symptoms: Results from the SEQUIOA-HCM Trial

Long-term Healthcare Costs and Utilization Among Patients With Non-Obstructive Hypertrophic Cardiomyopathy

Clinical and Economic Burden of Non-Obstructive Hypertrophic Cardiomyopathy: A Literature Review

Assessing Differences in Clinical Burden Across Payers for Non-Obstructive Hypertrophic Cardiomyopathy